CMC Drug Product Consulting ApS

CMC Drug Product Consulting ApS (CVR number: 38817566) is a company from HVIDOVRE. The company recorded a gross profit of 501.2 kDKK in 2023. The operating profit was -848.6 kDKK, while net earnings were -666.8 kDKK. The profitability of the company measured by Return on Assets (ROA) was -125.5 %, which can be considered poor and Return on Equity (ROE) was -177 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -62.2 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. CMC Drug Product Consulting ApS's liquidity measured by quick ratio was 0.4 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.